GSK partners with Australian scientists to make cheaper pediatric vaccines

GlaxoSmithKline is teaming up with researchers from Monash University in Melbourne, Australia, to develop new manufacturing methods to make vaccines cheaper for children in the developing world.

TSRI-led team tracks antibody origin, development in HIV vaccine work

With the research and knowledge aimed at developing a potential HIV vaccine continuing to mount, a team led by The Scripps Research Institute this week unveiled its research into a family of antibodies that could be capable of creating a broad response against the virus.

NIAID combines MedImmune, Sanofi H7N9 jabs into promising prime-boost vaccine

While H7N9 avian flu does not seem to move easily from person to person, the WHO notes that most people who catch it become severely ill. Several candidates for H7N9 pandemic flu have proven safe and immunogenic in clinical trials, but experts recommend that these be beefed up for practical use either via multiple doses or using an adjuvant. The National Institute of Allergy and Infectious Diseases reported Thursday that a team of scientists has successfully tested a prime-boost vaccine for the flu strain in a small clinical trial.

Sanofi off and running with launch of world's first dengue vaccine

Days after Sanofi received its first approval in Mexico for its pioneering dengue fever vaccine, it's said to be in discussions to bring the jab to India following a successful trial on an adult population there.

Allergy Therapeutics brings long-delayed grass allergy vax into PhII

U.K.-based Allergy Therapeutics is finally kicking off Phase II trials of its grass allergy vaccine in the U.S, announcing Monday that it has recruited its first trial participants. The trial will be a double-blind, placebo-controlled cumulative dose selection study.

Cerberus Capital management invests $105M in PaxVax

Redwood City, CA-based PaxVax currently markets one vaccine, Vivotif, the typhoid vaccine it acquired from Johnson & Johnson's Crucell in July 2014. But PaxVax could be on the way to adding its cholera candidate, Vaxchora, to the list thanks to a $105 million investment from Cerberus Capital management.

Japan's Kaketsuken covered up illicit blood product, vaccine production methods for 40 years

A whistleblower has tipped off Japanese authorities that Chemo-Sero-Therapeutic Research Institute (Kaktsuken), a manufacturer of blood products and vaccines, has been adding unauthorized ingredients to its products and falsifying data.

Second flu shot helps cancer patients stave off infection, Yale team says

A team from the Yale Cancer Center has devised a novel dosing schedule for flu vaccines aimed at increasing protection for cancer patients who are at a higher risk of contracting the viral infection.

U.S. Army, Hawaii Biotech join for dengue vaccine effort

Seeking a dengue fever vaccine that can offer broad protection in a short time, the U.S. Army has awarded Hawaii Biotech a Phase I contract to support the company's work against the "potentially mission-aborting" disease, according to a press release.

Novavax takes RSV vaccine into Phase III ahead of schedule

Novavax has been on a roll with its RSV (respiratory syncytial virus) vaccine lately, landing an $89 million Gates Foundation grant, reporting promising Phase II results in infants and launching a Phase III trial in older adults. Now, the Gaithersburg, MD-based biotech is starting a second Phase III trial in pregnant women to gauge the vaccine's efficacy in infants through maternal immunization.

Parents may be misled by inaccurate HPV vaccine websites, report says

A new study published in the Journal of Adolescent Health found that parents looking online for information about HPV vaccines can be misled by websites containing inaccurate or incomplete medical information, Reuters reported.

Analyst: Dynavax hep B vaccine positioned to grab market share from GSK's Engerix-B

Initially approved by the FDA in 1989, GlaxoSmithKline's Engerix-B has been the standard-of-care against hepatitis B. But an analyst thinks Dynavax's experimental Heplisav is poised to swipe some market share once it's approved.

NIAID to bring Chikungunya vaccine into Phase II

No specific treatment or vaccine currently exists for the mosquito-borne Chikungunya virus, but efforts are underway to remedy that. The NIH's National Institute of Allergy and Infectious Diseases (NIAID) will bring its experimental vaccine into Phase II, keeping up with Austria's Themis, which raised $7.9 million to do the same for its candidate last May.

Sanofi, Shantha to supply polio vaccines for India's universal immunization scheme

India will join more than 110 countries that have introduced the inactivated polio vaccine to their calendars. Sanofi and its Indian affiliate, Shantha Biotechnics, will supply polio vaccines to the Indian government via UNICEF. The vaccines will be used in India's universal immunization program.

Valneva's C. diff vaccine found to be 'highly immunogenic' in PhII

Valneva reported positive Phase II results this week for its GlaxoSmithKline-partnered C. difficile vaccine candidate, saying the shot proved to be "highly immunogenic" while also offering a good safety and tolerability profile.

FDA approves Seqirus' Fluad, the first U.S. adjuvanted flu vaccine

The U.S. has its first publicly available adjuvanted seasonal flu vaccine in Fluad, formerly a Novartis shot that is now owned by CSL's Seqirus unit.

Daiichi Sankyo, Sanofi to launch DPT-polio vaccine in Japan

In the latest of a string a partnerships forged this year, Daiichi Sankyo is teaming up with Sanofi's Japanese unit to launch Squarekids subcutaneous injection syringe, a tetravalent vaccine for the prevention of diphtheria, pertussis, tetanus and polio.

BYU team devises method to speed up vaccine production

Brigham Young University researchers have developed a "just add water" method to expedite vaccine production in the face of new viruses. The process involves creating vaccine production machinery en masse and then freeze-drying it and stockpiling it in different locations.

FDA expands indication of Emergent BioSolutions anthrax vaccine

The FDA has expanded the indication of Emergent BioSolutions' BioThrax anthrax vaccine for use in adults aged 18 to 65 in conjunction with antibiotic treatment, following confirmed or suspected exposure to Bacillus anthracis.

SUNY Upstate Medical University, U.S. Army start $12M partnership toward dengue vaccine

Sanofi is the furthest along in the race for a dengue vaccine, expecting its first license to market its jab by the end of the year. But this doesn't mean others aren't trying to tackle the mosquito-borne disease: SUNY Upstate Medical University announced on Monday a $12 million partnership with the U.S. Army to develop a dengue vaccine.